[Treatment of migraine: analgetic plus antiemetic or tryptan].
Medical treatment of migraine has the twofold task of cutting short an acute attack and preventing further episodes. Mild attacks are treated with analgesics and antiemetics. Fixed combination preparations are associated with the risk of analgesic-induced headaches and nephropathy and should not be employed. Severe attacks are treated with triptanes, depending on a number of features of the attack. A "migraine status" requires a special approach. When migraine occurs on more than seven days a month, prophylactic measures are indicated with the aim of preventing drug-induced headache. The objective is a 50% reduction in the number of attacks.
Göbel
H
H
Neurologisch-verhaltensmedizinische Schmerzklinik Kiel, Universität Kiel, Heikendorfer Weg 9-27, D-24149 Kiel. kiel@schmerzklinik.de
D000284:Administration, Oral; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D004359:Drug Therapy, Combination; D004630:Emergencies; D005260:Female; D006261:Headache / Q000139:chemically induced; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008881:Migraine Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D011247:Pregnancy; D012008:Recurrence; D013997:Time Factors; D014364:Tryptophan / Q000627:therapeutic use*
D000700:Analgesics; D018687:Antidepressive Agents, Second-Generation; D000932:Antiemetics; D014364:Tryptophan